Ketorolac Tromethamine

syntex · TORADOL · Ketorolac (Toradol) · Ketorolac Thromethamine · KETOROLAC TROMETHAMINE SALT · Godek · Ketanov · Ketorol

https://huagongshe.com/de/chemical/84003

Molekülstruktur von Ketorolac Tromethamine

Identifikatoren & physikalische Daten

CAS No.	74103-07-4
Summenformel	C19H24N2O6
Durchschnittliche Molmasse	376,4 g/mol
Monoisotopische Masse	376,16343649 g/mol
SMILES	NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
InChIKey	BWHLPLXXIDYSNW-UHFFFAOYSA-N
PubChem CID	84003
ChEMBL	CHEMBL1201124
EC No.	620-545-3
DTXSID	DTXSID0045597

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)	146
H-Brücken-Donoren	5
H-Brücken-Akzeptoren	7
Frei drehbare Bindungen	6
Schwere Atome	27
Formalladung	0
Komplexität	430
Löslichkeit	>56.5 [ug/mL] (The mean of the results at pH 7.4)H2O: 15 mg/mL stable at least one month at −20 °C., solubleH2O: soluble 15mg/mL, clear, colorless to faintly yellow (stable at least one month at -20 °C.)
Collision Cross Section	155.6 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
Schmelzpunkt	160-161 C
Lagerbedingungen	2-8°C
Aggregatzustand	crystalline
Farbe	White to Light yellow
Biologische Quelle	synthetic (organic)
Merck	14,5306
Stabilität	Hygroscopic
InChI	InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)135-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19)6-8H,1-3,5H2
InChIKey	BWHLPLXXIDYSNW-UHFFFAOYSA-N
SMILES	C(N)(CO)(CO)CO.C(C1C=CC=CC=1)(C1=CC=C2C(C(=O)O)CCN12)=O
CAS Datenbank	74103-07-4(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-Einstufung	DangerH301 (96.9%): Toxic if swallowed [Danger Acute toxicity, oral]H315 (93.8%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (93.8%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (92.2%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 64 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Hazard Classes and Categories	Acute Tox. 3 (96.9%)Skin Irrit. 2 (93.8%)Eye Irrit. 2 (93.8%)STOT SE 3 (92.2%)
Drug Induced Liver Injury	Drug Induced Liver Injury Rank (DILIrank 2.0)Ketorolac tromethaminevLess-DILI-concern3Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation	◉ Summary of Use during LactationMilk levels of ketorolac are low with the usual oral dosage, but milk levels have not been measured after higher injectable dosages or with the nasal spray. Ketorolac injection is used for a short time (typically 24 hours) after cesarean section in some hospital protocols with no evidence of harm to breastfed infants. However, the ketorolac dose an infant receives in colostrum is very low because of the small volume of colostrum produced. Some evidence suggests that IV ketorolac as part of a multimodal post-cesarean section analgesia reduces percentage of mothers who fail exclusive breastfeeding compared to patient-controlled IV morphine-based analgesia. Ketorolac has strong antiplatelet activity and can cause gastrointestinal bleeding. The manufacturer indicates that ketorolac is contraindicated during breastfeeding, so an alternate drug is preferred after the first 24 to 72 hours when larger volumes of milk are produced, especially while nursing a newborn or preterm infant.

Anwendungen & Verwendung

Beschreibung

Ketorolac tromethamine is a nonsteroidal antiinflammatory agent that exhibits analgesic and antipyretic activity. The compound is effective in the management of moderate to severe postoperative pain. It is, however, the first of this type of agent to be administered parenterally as an analgesic and is specifically indicated for intramuscular injection. Ketorolac represents a useful alternative to the narcotic analgesics due to its lack of abuse potential.

Verwenden

Cyclo-oxygenase inhibitor; analgesic; anti-inflammatory.